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ORIGINAL ARTICLE

A multicenter randomized controlled trial of a plant-based
nutrition program to reduce body weight and cardiovascular risk
in the corporate setting: the GEICO study
S Mishra1, J Xu1, U Agarwal1, J Gonzales1, S Levin1 and ND Barnard1,2
BACKGROUND/OBJECTIVES: To determine the effects of a low-fat plant-based diet program on anthropometric and biochemical
measures in a multicenter corporate setting.
SUBJECTS/METHODS: Employees from 10 sites of a major US company with body mass index X25 kg/m2 and/or previous
diagnosis of type 2 diabetes were randomized to either follow a low-fat vegan diet, with weekly group support and work cafeteria
options available, or make no diet changes for 18 weeks. Dietary intake, body weight, plasma lipid concentrations, blood pressure
and glycated hemoglobin (HbA1C) were determined at baseline and 18 weeks.
RESULTS: Mean body weight fell 2.9 kg and 0.06 kg in the intervention and control groups, respectively (Po0.001). Total and
low-density lipoprotein (LDL) cholesterol fell 8.0 and 8.1 mg/dl in the intervention group and 0.01 and 0.9 mg/dl in the control
group (Po0.01). HbA1C fell 0.6 percentage point and 0.08 percentage point in the intervention and control group, respectively
(Po0.01). Among study completers, mean changes in body weight were  4.3 kg and  0.08 kg in the intervention and control
groups, respectively (Po0.001). Total and LDL cholesterol fell 13.7 and 13.0 mg/dl in the intervention group and 1.3 and 1.7 mg/dl in
the control group (Po0.001). HbA1C levels decreased 0.7 percentage point and 0.1 percentage point in the intervention and control
group, respectively (Po0.01).
CONCLUSIONS: An 18-week dietary intervention using a low-fat plant-based diet in a corporate setting improves body weight,
plasma lipids, and, in individuals with diabetes, glycemic control.
European Journal of Clinical Nutrition (2013) 67, 718–724; doi:10.1038/ejcn.2013.92; published online 22 May 2013
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INTRODUCTION
Approximately two-thirds of Americans are currently overweight,
half of whom are obese.1 Obesity is associated with increased risk
of serious health conditions, including type 2 diabetes,
cardiovascular disease, hypertension and certain cancers that
account for about 75% of the $2 trillion spent on medical care
each year.2
The workplace is an ideal location for nutritional interventions. It
is where many individuals make dietary choices, receive health
information and spend much of their day. Employers have an
economic interest in employee health, particularly given that
obesity is associated with increased use of sick leave and disability
expenditures,3 reduced job productivity and increased
absenteeism.4 In a 2010 study, the total cost of obesity in the
workplace was estimated to be $73.1 billion, 41% of which could
be attributed to reduced productivity, 18% to absenteeism and
41% to medical expenditures.4
A prior study of a dietary intervention involving two corporate
sites of the Government Employees Insurance Company (GEICO),
a major US insurance company with about 27 000 employees
nationally, demonstrated that a low-fat plant-based diet led to

favorable changes in body weight, plasma lipid concentrations
and glycemic control.5 A plant-based diet was selected because
studies had shown that people following vegetarian and nearvegetarian diets have signiﬁcantly lower prevalence of obesity,6,7
type 2 diabetes,8,9 heart disease,10 hypertension,11 cancer12 and
gallbladder disease,13 compared with non-vegetarians. In clinical
trials, low-fat plant-based diets reduce body weight and blood
pressure, and improve plasma lipid concentrations and glycemic
control.14,15
We conducted the present multicenter study to evaluate the
effects of a low-fat plant-based diet on health outcomes in a larger
and more geographically diverse sample of GEICO employees.

MATERIALS AND METHODS
Study population
Men and women 418 years of age with a body mass index (BMI) X25 kg/m2
and/or a previous diagnosis of type 2 diabetes were recruited through
advertisements and group meetings at 10 GEICO corporate ofﬁces
encompassing over 20 000 employees, in Tucson, Arizona; San Diego,
California; Lakeland, Florida; Macon, Georgia; Chevy Chase, Maryland;
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Buffalo, New York; Woodbury, New York; Dallas, Texas; Fredericksburg,
Virginia and Virginia Beach, Virginia. Exclusion criteria included current
alcohol or drug abuse, pregnancy, history of severe mental illness, unstable
medical status, current adherence to a low-fat, vegetarian diet, participation in the previous GEICO two-site study and inability to attend weekly
meetings. Worksites were then pair-matched by race and each pair of sites
represented a cluster. The sites within each pair (cluster) were randomly
assigned to the intervention group (ﬁve sites) or control group (ﬁve sites)
using a random-number table. As assignment was done by site rather than
by individual, all participants at a given site were in the same assigned
group. The study was approved by an external institutional review board,
and all participants provided written informed consent.

Intervention program
Participants at intervention sites were asked to follow a low-fat vegan diet
consisting of whole grains, vegetables, legumes, and fruits, with no
restriction on energy intake for 18 weeks. They were asked to avoid animal
products (that is, meat, poultry, ﬁsh, dairy products and eggs) and to
minimize added oils, with a target of o3 g of fat per serving. They were
also encouraged to favor foods with a low glycemic index, which have been
shown to decrease triglyceride concentrations16 and increase insulin
sensitivity independent of effect on body weight.14,17 Intervention group
participants were asked to take a daily supplement of vitamin B12. At
intervention sites with cafeterias, low-fat vegan menu options were made
available, such as oatmeal, minestrone or lentil soup, veggie burgers and
portobello mushroom sandwiches among the daily offerings. The low-fat
vegan menu options were highlighted in the cafeteria, but the daily vegan
options varied depending on the individual cafeterias. A sample of the menu
followed by the participants in the intervention group is shown in Figure 1.
The participants at the intervention sites were asked to follow a low-fat
vegan diet for 18 weeks. They were provided group support in a total of
18, weekly lunch-hour classes held at the worksite for the duration of the
study. The classes were led by a registered dietitian, physician and/or a
cooking instructor. All instructors received training in study procedures
and followed predetermined identical instruction materials (curriculum,
handouts, videos, cooking instructions, and so on). Classes included
nutrition education lecture videos on topics such as the effects of diet on
weight loss, diabetes, heart disease and cancer, as well as cooking
demonstrations and group discussion. Individuals at intervention sites
were not compensated.
Individuals at control sites made no dietary changes, were given no dietary
guidance and no additional food was made available in those sites. They were
given $50 gift certiﬁcates for completion of all aspects of the study.
All participants were asked not to alter their exercise patterns during the
study period. Participants were asked to continue their pre-existing
medication regimens unless modiﬁed by their personal physician. No
restrictions were placed on use of medications during the study.
Information on current medication use was collected at baseline and
week 18.

Measurements
The following measures were assessed at weeks 0 and 18:
A 24-h diet recall was used to assess nutrient intake over two 24-h
periods, using an online program (ASA24; Automated Self-Administered
24-hour Recall) developed by the National Cancer Institute, Bethesda, MD,
USA (http://riskfactor.cancer.gov/tools/instruments/asa24/).
The format and design of the online program were modeled on the
interviewer-administered Automated Multiple Pass Method 24-h recall
developed by the US Department of Agriculture. Participants with
implausible energy intake (o800 or 44000 kcal per day among men
and o500 and 43500 kcal per day among women) were excluded from
nutrient data analyses.
Body weight was measured with participants wearing light, indoor
clothing without shoes, using a digital scale (Befour Inc., Saukville, WI, USA;
model number FS-0900, Health & Fitness Stand-on Scale). Height was
measured with participants standing barefoot with their backs to a wallmounted stadiometer and heels against the wall.
Digital blood pressure monitor (Omron Healthcare, Inc., Kyoto, Japan,
model number Omron HEM780) was used to measure blood pressure.
Three measurements were taken at 1-min intervals. The mean of the last
two measurements was calculated.18
Blood samples were collected in the morning after a 12-h fast. Plasma
cholesterol and triglyceride concentrations were measured using an
& 2013 Macmillan Publishers Limited

Abbott Spectrum analyzer (Abbott Laboratories, Abbott Park, IL, USA) by
enzymatic methods.19 High-density lipoprotein (HDL) cholesterol
concentration was measured after double precipitation with dextran and
MgCl2.20 Low-density lipoprotein (LDL) cholesterol concentration was
estimated using the Friedewald equation.21 In cases where triglycerides
exceeded 400 mg/dl, LDL was measured by afﬁnity chromatography. For
participants with diabetes, HbA1C was measured by immunoturbidimetric
determination (Gen.2, Tina-Quant, Whole Blood Application on the Roche
Integra 800, Roche Diagnostics, Basel, Switzerland). All laboratory tests were
conducted by Quest Diagnostics (Quest Diagnostics, Madison, NJ, USA).
At the conclusion of the intervention period, individuals in the control
group were offered the same series of 18 total dietary instructional sessions
as had been provided to the intervention group. Weight, blood pressure,
cholesterol, triglycerides and HbA1C were measured before and after an 18week period for this group, using the methods described above.

Statistical analysis
A power analysis, using the previous GEICO study showed that an effect
size was 40.30 for the following clinical variables (weight, total
cholesterol, HDL cholesterol and blood pressure). With the effect size
40.30, a of 0.05 and power of X80%, a sample of 175 subjects in each
group was required to detect a statistical signiﬁcance between the two
groups. Assuming a 20% drop out, 210 participants were required per
group. If this sample could not be achieved in the initial study, a replication
could be considered.
Distributions of variables were examined for skewness. T-tests and
w2 tests identiﬁed measures that were unbalanced between groups at
baseline so as to be included as covariates in subsequent analyses. As
exclusion of outliers did not alter results, results are presented without
such exclusions.
An intention-to-treat analysis was performed on dietary and clinical
variables, where participants who did not complete 18-week assessments
were deemed to have had no change from baseline. Participants who did
not complete clinical baseline assessments were not accepted into the
study. Within-group changes were determined by paired t-tests. Betweengroup changes were determined by t-tests and general linear model
univariate analysis (analysis of covariance), where treatment group, gender,
cluster and medication changes were included as ﬁxed factors and
baseline variables as covariates. w2 tests determined whether there were
differences between groups regarding the number of participants losing
X5% of body weight.
A separate analysis was performed on those participants who completed
18-week assessments to determine the effect of the intervention on clinical
variables among program completers. A supplemental analysis was
conducted on those participants who did not change their medications
during the course of the study.
All analyses were conducted using SPSS version 18.0. (IBM, Armonk, NY,
USA) P-values o0.05 were considered signiﬁcant.

RESULTS
Study population
Of the 319 participants screened for eligibility, 291 (142 at
intervention sites and 149 at control sites) met the participation
criteria and were enrolled in the study. Twenty eight participants
did not meet the participation criteria and were excluded owing
to various reasons, as described in Figure 1. The intervention sites
were in Tucson, Macon, Chevy Chase, Lakeland and Buffalo. The
control sites were in San Diego, Woodbury, Fredericksburg, Dallas
and Virginia Beach. There was no difference in the baseline
characteristics among volunteers excluded before randomization
and those who were enrolled (P-value ranged from 0.1 to 0.8).
Ninety-four of 142 (66%) intervention-group participants and
117 of 149 (79%) control-group participants completed anthropometric and laboratory assessments at 18 weeks. Eighty
participants dropped out owing to various reasons, as described
in Figure 2. At baseline, no signiﬁcant differences were found
between the intervention and control groups for any demographic or clinical measures except gender, with fewer men and
more women in the control group (P ¼ 0.02) (Table 1). There were
no intervention-related serious adverse events.
European Journal of Clinical Nutrition (2013) 718 – 724
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Dietary intake and adherence
Diet recalls were completed at baseline by 94% of participants in
the intervention group and 95% in the control group, and at 18
weeks by 61% of participants in the intervention group and 73%
in the control group. Fourteen intervention-group and eight
control-group participants had implausible energy intake values at
baseline and were excluded from the dietary analysis. At baseline,
there were no signiﬁcant group differences in energy, protein or
total fat intake, although there were small differences in
carbohydrate and ﬁber intake (Table 2). Dietary total fat and
saturated fat intake were calculated as a gauge of adherence to
the diet. Compared with the control group, total fat, saturated fat,
protein and cholesterol intakes decreased signiﬁcantly in the
intervention group, while ﬁber intake increased at 18 weeks. The
difference in total and saturated fat intakes was signiﬁcant
between the two groups at 18 weeks (Table 2).
As animal products are the only signiﬁcant source of dietary
cholesterol, cholesterol intake was used as an additional gauge of
adherence. Cholesterol intake was p50 mg/day among 47%
and 12% of participants in the intervention and the control
group, respectively. Total fat intake was p25% of energy among
30% and 6% of participants in the intervention and the control
group, respectively. Saturated fat intake was p5% of energy
among 29% and 4% of participants in the intervention and the
control group, respectively.

BREAKFAST
Oatmeal with cinnamon and raisins
Soy/rice milk
Pumpernickel toast with jam
Grapefruit
Or
Whole-grain bagel with apple butter
Veggie bacon
Cantaloupe
LUNCH
Whole-wheat pita stuffed with hummus
Sliced tomatoes and lettuce carrot sticks
Or
Bean burritos (black beans in corn tortillas, chopped lettuce, tomatoes, and salsa) and
spinach salad with low-fat dressing
DINNER
Baked beans or baked sweet potato and steamed collard greens with lemon juice
Baked apple
Or
Chinese stir-fry over brown rice (tofu, broccoli, pea pods, water chest- nuts, bok coy)
Cantaloupe chunks drizzled with fresh lime juice

Anthropometric variables
Including all participants in the analysis, mean body weight
decreased 2.9 kg in the intervention group and 0.06 kg in the
control group (Po0.001). BMI fell by 1.04 kg/m2 in the intervention

SNACKS
Dried figs/ mixed fruit salad/ baked corn tortillas with salsa

Figure 1.

Low fat vegan menu sample.

319 volunteers assessed for eligibility

Excluded = 28
21 did not meet inclusion criteria or had ≥ 1
exclusion criteria
2 participated in previous GEICO study
3 already following a plant-based diet
2 unable to attend weekly meetings
6 pregnant
8 low BMI
4 left GEICO
1 did not provide consent
2 failed to complete individual screening

291 randomized

142 were assigned to the
intervention diet

48 discontinued the study
3 had schedule conflicts with weekly meetings
5 never came to group meeting
1 developed psychiatric illness
36 had unspecified reasons
3 left GEICO

149 were assigned to the control
group

32 discontinued the study
4 left employment or retired
1 was asked by personal physician to discontinue
participation
1 refused group assignment
1 relocated
25 had unknown reasons

94 assessed at 18 weeks
117 assessed at 18 weeks

Figure 2.

Recruitment and flow of participants through trial.
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Abbreviations: CI, confidence interval. All values mean ±s.e.m. *P-value for analysis adjusted for gender, baseline value and medication change. **Po0.001. ***Po0.01. ****Po0.05. aUnadjusted (from t-test)
b
Gender, baseline value and cluster adjusted (analysis of covariance).

o0.001
0.001
 92 (  141.5 to  42.6)
4.6 (1.9 to 7.2)
 93.8 (  151.6 to  36)***
2.8 (  0.1 to 5.7)
 13.9 (19.6)
0.74 (0.72)
226.6 (18.6)
16.8 (0.8)
240.5 (15.3)
16.0 (0.7)
136.3 (18.1)
22.9 (1.3)
244.0 (18.8)
19.3 (1.2)

 107.7 (21.9)**
3.5 (1.3)***

0.16
56.6 (1.3)
50.1 (1.1)

6.4 (1.2)

o0.001
 6.7 (  9.7 to  3.7)

16.9 (  6.9 to 40.9)
47.6 (0.9)

47.5 (0.9)

 0.07 (0.9)

6.5 (3.5 to 9.5)

**
**

 2.4 (  3.7 to  1.2)**
 0.36 (0.45)
12.0 (0.4)

11.6 (0.4)

o0.001
 15.2 (  22.7 to  7.6)

 2.8 (0.4)**

Macronutrient changes by group assignment

Table 2.

Plasma lipid concentrations and blood pressure
Including all study participants, changes in total cholesterol were
 8.0 mg/dl in the intervention group and  0.01 mg/dl in the
control group (Po0.01). LDL cholesterol fell 8.1 mg/dl in the
intervention group and 0.9 mg/dl in the control group (Po0.01).
HDL cholesterol decreased 1.8 mg/dl in the intervention group
and increased 0.9 mg/dl in the control group (Po0.01). Triglycerides increased 9.9 mg/dl in the intervention group and decreased
1.4 mg/dl in the control group (Po0.05). These differences
remained signiﬁcant after adjusting for gender, baseline measures,
cluster and medication changes (Po0.001 for total, LDL and HDL
cholesterol; Po0.02 for triglycerides). There was no signiﬁcant
difference in the changes in total:HDL cholesterol ratio among
intervention- and control-group participants (Table 3).
Analyses limited to those with no medication changes did not
substantially differ from those for the full sample (data not shown).
Among participants with baseline triglyceride values o150 mg/
dl, triglyceride levels increased 18.1 mg/dl in the intervention
group and 6.7 mg/dl in the control group (P ¼ 0.02). There was no
signiﬁcant difference in the changes in mean triglyceride
levels among intervention- and control-group participants with
triglycerides X150 mg/dl at baseline.
Limiting the analysis to study completers, total cholesterol
fell 13.7 mg/dl in the intervention group and 1.3 mg/dl in the
control group, (Po0.001). LDL cholesterol fell 13.0 mg/dl in the

Control group (n ¼ 135)

group and 0.01 kg/m2 in the control group, (Po0.001). The
between-group differences remained signiﬁcant after taking into
account gender, baseline values, cluster and medication changes
(Po0.001; Table 3). Weight loss of X5% of body weight was more
frequent in the intervention group (37%) compared with the
control group (11%; Po0.001).
Limiting the analysis to the participants who completed the
18-week assessments, mean body weight decreased by 4.3 kg in
the intervention group and 0.08 kg in the control group
(Po0.001). BMI fell 1.5 kg/m2 in the intervention group and
0.02 kg/m2 in the control group, Po0.001. The between-group
differences remained signiﬁcant after adjusting for gender, cluster
and baseline values (Po0.001; Table 4).

8.5 (0.5)

P-values refers to w2 square test for categorical variables and t-test for
continuous variable for differences between groups.

11.3 (0.4)

a

 3.7 (  6.2 to  1.2)***

(71%)
(17%)
(7%)
(6%)

 0.38 (0.86)

106
25
10
9

36.8 (0.7)

(63%)
(24%)
(5%)
(8%)

37.2 (0.7)

0.36
90
34
7
11

 4.1 (0.9)**

10 (7%)
140 (93%)

31.0 (1.0)

0.17
16 (11%)
126 (89%)

35.1 (0.9)

0.30

 130 (  281 to 20.4)
 12.9 (  19.6 to  6.4)

(65%)
(27%)
(3%)
(4%)

 228(  400 to  56.1)****
 1.7 (  2.9 to  0.4)****

98
41
5
6

 36.8 (58)
0.5 (0.5)

Occupation n (%)
Sales/service
Supporting staff
Professional
Other

(62%)
(24%)
(7%)
(7%)

1690.7 (58.4)
17.0 (0.5)

Ethnicity n (%)
Hispanic
Non-Hispanic

88
34
10
10

Between-group difference in
change score, mean,
unadjusteda (95% CI)

Race n (%)
White
Black
Asian
Other

1727.5 (50.3)
16.5 (0.4)

0.02

 264.6 (65.6)**
 1.2 (0.4)***

18 (12%)
132 (88%)

1623 (59)
14.6 (0.41)

32 (23%)
110 (77%)

1887 (65)
15.7 (0.37)

Gender n (%)
Men
Women

Energy (kcal)
Protein, % of
total energy
Total Fat, % of
total energy
Saturated fat, %
of total energy
Carbohydrate, %
of total energy
Cholesterol (mg)
Fiber (g)

0.29

Within-group
difference

46.1 (13.6)

18-week
mean

44.3 (15.3)

Baseline
mean

Age, years (s.d.)

Within-group
difference

P-valuea

18-week
mean

Control
(n ¼ 149)

Baseline
mean

Intervention
(n ¼ 142)

Between-group difference in
change score, mean,
adjusted* (95% CI)

Characteristics

P-valueb

Baseline characteristics by group assignment

Intervention group (n ¼ 119)

Table 1.

0.09
o0.001
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96.5
34.7
186.3
107.9
53.7
3.7
123.6
126.5
82.3
7.54

(1.9)
(0.6)
(3.4)
(2.8)
(1.4)
(0.1)
(5.5)
(1.2)
(0.8)
(0.42)

93.6
33.7
178.3
99.8
52.0
3.7
133.5
124.8
80.0
6.94

(1.9)
(0.6)
(3.1)
(2.6)
(1.3)
(0.1)
(5.6)
(1.1)
(0.8)
(0.40)

18-week
mean
 2.9
 1.04
 8.0
 8.1
 1.8
 0.05
9.9
 1.7
 2.4
 0.60

(0.34)**
(0.1)**
(2.1)**
(1.8)**
(0.6)***
(0.04)
(3.8)****
(0.7)****
(0.6)**
(0.17)****

Within-group
difference
96.4
35.3
188.9
108.5
56.7
3.5
119.4
127.2
81.6
7.05

(1.9)
(0.7)
(3.2)
(2.8)
(1.2)
(0.1)
(5.3)
(1.3)
(0.8)
(0.32)

Baseline
mean
96.4
35.3
188.9
107.6
57.7
3.4
118.0
124.5
79.4
7.13

(1.9)
(0.7)
(3.0)
(2.6)
(1.2)
(0.1)
(5.0)
(1.1)
(0.7)
(0.34)

18-week
mean
 0.06
 0.01
 0.01
 0.9
0.9
 0.07
 1.4
 2.8
 2.0
 0.08
(0.33)
(0.1)
(1.5)
(1.4)
(0.6)
(0.03)
((3.3)
(0.9)***
(0.5)**
(0.09)

Within-group
difference

Control (n ¼ 149)

 2.9
 1.1
 8.0
 7.2
 2.7
0.02
11.4
1.2
 0.2
 0.68

(  2.0 to  3.9)**
(  1.4 to  0.7)**
(  13.1 to  2.9)***
(  11.8 to  2.7)***
(  4.4 to  1.1)***
(  0.1 to 0.13)
(1.4 to 21.3)****
(  1.1 to 3.4)
(  1.7 to 1.4)
(  0.29 to  1.1)****

Between-group difference in
change score, mean,
unadjusteda (95% CI)

 2.8
 1.0
 8.5
 7.2
 3.1
0.02
10.7
0.9
0.4
 0.7

(  3.8 to  1.8)
(  1.4 to  0.7)
(  13.1 to  3.8)
(  11.4 to  3.0)
(  4.6 to  1.6)
(  0.1 to 0.12)
(1.5 to 20)
(  1.1 to 2.9)
(  0.9 to 1.8)
(  1.2 to  0.2)

Between-group
difference in change
score, mean,
adjustedb(95% CI)

o0.001
o0.001
o0.001
o0.001
o0.001
0.77
0.02
0.38
0.54
0.004

P-value*

93.3
33.5
189
109
55
3.7
129
127
83
7.52

(2.1)
(0.6)
(4.3)
(3.7)
(1.8)
(0.1)
(7.0)
(1.6)
(1.1)
(0.49)

89
32
176
96
51
3.7
143
124
79
6.78

(2.0)
(0.6)
(4.2)
(3.4)
(1.7)
(0.1)
(7.1)
(1.4)
(1.0)
(0.44)

 4.3
 1.5
 13.7
 13.0
 3.3
 0.07
13.9
 2.6
 3.5
 0.74

(0.4)**
(0.2)**
(3.5)**
(2.8)**
(1.1)***
(0.06)
(5.6)****
(1.0)****
(0.8)**
(0.19)***
93.5
34
191
110
56
3.6
127
127
81
7.03

(1.9)
(0.6)
(3.5)
(3.2)
(1.4)
(0.9)
(6.28)
(1.4)
(0.9)
(0.36)

93.4
34
189
108
56.7
3.5
124
123
79
7.13

(1.9)
(0.6)
(3.5)
(3.0)
(1.3)
(0.8)
(5.9)
(1.0)
(0.8)
(0.38)

18-week
mean

Baseline
mean

Within-group
difference

Baseline
mean

18-week
mean

Control (n ¼ 119)

Intervention (n ¼ 96)

 0.08 (0.4)
 0.02 (0.1)
 1.3 (2.3)
 1.7 (1.9)
0.7 (0.9)
 0.08 (0.05)
 2.9 (4.3)
 3.6 (1.1)***
 2.6 (0.7)**
 0.10 (0.12)

Within-group
difference
 4.3
 1.6
 12.3
 11.3
3.9
0.01
16.8
0.9
 0.8
 0.84

(  3.2 to  5.5)**
(  1.1 to  1.9)**
(  4.3 to  20.3)***
(  17.8 to  4.8)***
(  6.6 to  1.3)***
(  0.1 to 0.1)
(3.1 to 30.6)****
(  2.1 to 4.1)
(  2.9 to 1.1)
(  0.37 to  1.1)***

Between-group difference in
change score, mean,
unadjusteda (95% CI)

 4.3
 1.6
 12.6
 11.1
 4.1
0.04
14.1
0. 8
0.4
 0.7

(  5.5 to  3.1)
(  2.0 to  1.1)
(  20.1 to  4.9)
(  17.2 to  5.1)
(  6.6 to  1.6)
(  0.1 to 0.19)
(1.3 to 27)
(  1.9 to 3.1)
(  2.2 to 1.4)
(  1.2 to  0.3)

Between-group difference in
change score, mean,
adjustedb (95% CI)

o0.001
o0.001
0.001
o0.001
0.001
0.63
0.03
0.60
0.64
0.003

P-value*

Abbreviations: BMI, body mass index; CI, confidence interval; HDL, high-density lipoprotein; LDL, low-density lipoprotein. All values mean±s.e.m. unless otherwise specified *P-value for analysis adjusted for
gender, cluster and baseline value. **Po0.001. ***Po0.01. ****Po0.05. aUnadjusted (from t-test). bGender, cluster and baseline value (analysis of covariance).

Weight (kg)
BMI (kg/m2)
Total cholesterol (mg/dl)
LDL cholesterol (mg/dl)
HDL cholesterol (mg/dl)
Total:HDL cholesterol ratio
Triglycerides (mg/dl)
Systolic blood pressure (mm Hg)
Diastolic blood pressure (mm Hg)
Hemoglobin A1c, % (n ¼ 17 diet
group; control group n ¼ 18)

Clinical measure

Table 4. Changes in clinical variables by group assignment among program completers

Abbreviations: BMI, body mass index; CI, confidence interval; HDL, high-density lipoprotein; LDL, low-density lipoprotein. All values mean±s.e.m. unless otherwise specified. *P-value for analysis adjusted for
gender, cluster, medication change and baseline value. **Po0.001. ***Po0.01. ****Po0.05. aUnadjusted (from t-test) bGender, cluster, medication change and baseline value adjusted (analysis of covariance).

Weight (kg)
BMI (kg/m2)
Total cholesterol (mg/dl)
LDL cholesterol (mg/dl)
HDL cholesterol (mg/dl)
Total:HDL cholesterol ratio
Triglycerides (mg/dl)
Systolic blood pressure (mm Hg)
Diastolic blood pressure (mm Hg)
Hemoglobin A1c, % (n ¼ 21 diet
group; control group n ¼ 22)

Baseline
mean

Intervention (n ¼ 142)

Changes in clinical variables by group assignment among all participants

Clinical measure

Table 3.
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intervention group and 1.7 mg/dl in the control group (Po0.001).
HDL cholesterol decreased 3.3 mg/dl in the intervention group
and increased 0.7 mg/dl in the control group (Po0.01). Triglycerides increased 13.9 mg/dl in the intervention group and decreased
2.9 mg/dl in the control group (Po0.05). These differences
remained signiﬁcant after adjusting for gender, baseline measures
and cluster. There was no signiﬁcant difference in the changes in
total:HDL cholesterol ratio among intervention- and control-group
participants (Table 4).
Systolic and diastolic blood pressures fell slightly in both
groups, with no signiﬁcant between-group differences (Table 3).
An analysis limited to medication-stable participants yielded a
similar result.
Hemoglobin A1c in participants with diabetes
Including all participants with type 2 diabetes, mean HbA1C levels
decreased 0.6 percentage point and 0.08 percentage point in the
intervention and control group, respectively, (Po0.01). This
difference remained signiﬁcant after adjusting for gender, baseline measures, cluster and medication changes (P ¼ 0.004, Table 3).
Limiting the analysis to those with no medication changes did not
substantially alter the result (data not shown).
Limiting the analysis to participants with type 2 diabetes who
completed 18-week assessments, mean HbA1C decreased
0.7 percentage point within the intervention group and 0.1
percentage point in the control group (Po0.01). This difference
remained signiﬁcant after adjusting for gender, cluster and
baseline measures (P ¼ 0.003, Table 4).
For those members of the control group who, at the conclusion
of the regular study period, began the optional vegan diet
program, clinical changes at 18 weeks were as follows. In
intention-to-treat analysis (N ¼ 119), the average reduction
in body weight was 3.03 kg (Po0.001) and BMI reduced by
1.07 kg/m2 (Po0.001) at 18 weeks. On average, the total
cholesterol was reduced by 3.03 mg/dl (P ¼ 0.04) and HDL
cholesterol by 1.78 mg/dl (P ¼ 0.003). Limiting the analysis to
those who completed both the baseline and 18-week assessments
(N ¼ 94), the average reduction in body weight was 3.84 kg
(Po0.001) and HDL cholesterol reduced by 2.11 mg/dl (P ¼ 0.03).

DISCUSSION
The need for nutrition intervention programs in work settings is
driven by both medical and economic concerns. Obesity, diabetes,
cardiovascular disease and other diet-related diseases continue to
take a major toll worldwide. In the United States, these illnesses
exact a ﬁnancial toll, much of which is borne by employers. An
estimated 25–30% of medical costs incurred by employers are
attributable to excess risk associated with speciﬁc factors,
including overweight, heart disease, lipid disorders, diabetes and
hypertension, among others.22 A previous two-center study
suggested that the beneﬁts of plant-based diets seen in clinical
settings may also be realized in the workplace. A plant-based
dietary intervention was associated with signiﬁcant weight loss5
and was both nutritious23 and well accepted.24 The present study
extends those ﬁndings to a larger sample in corporate settings in
regions throughout the United States.
In this randomized, controlled trial, a nutrition intervention at
the workplace yielded signiﬁcant improvements in body weight,
plasma lipids and glycemic control among diabetics. Changes in
these variables in the intervention group were greater than that in
the control group, and were statistically and clinically signiﬁcant.
Although many intervention-group participants had less than
complete adherence to the prescribed diet, dietary changes were
substantial, and signiﬁcant changes in anthropometric and clinical
variables were evident.
& 2013 Macmillan Publishers Limited

The weight changes observed in the present study were similar
to those seen with plant-based diets in observational or research
settings.25 It is noteworthy that a plant-based diet causes weight
loss even in the absence of caloric restriction and exercise.25
Weight reduction appears to result from early satiety due to
higher dietary ﬁber intake, leading to a drop in energy intake. The
difference in weight loss could also be the result of an increase in
the thermic effect of food, allowing a small extra edge for weight
loss in the vegan group. A low-fat vegan diet increases insulin
sensitivity in cells, allowing cells to metabolize glucose more
quickly rather than storing it as body fat. As a result, vegan diets
have been shown to increase postprandial calorie burn by about
16%, up to 3 h after consuming a meal.26 A 2007 study showed
that the weight loss caused by a short-term dietary intervention
with a plant-based diet was partially maintained over 2 years of
follow-up.27
The reductions in mean fat intakes, saturated fat and cholesterol
intakes in the intervention group were similar to those seen with a
plant-based diet in previous studies.23,28 The reductions in
circulating levels of total and LDL cholesterol observed with
plant-based diets are caused by the absence of animal fat, as well
as by the lipid-lowering effect of certain plant-based foods,29 and
are typically greater than those seen with more moderate diets.30
Low-fat vegetarian diets showing decreases in HDL cholesterol are
not associated with poor cardiovascular health in observational
studies,31,32 and have been shown to improve atherosclerotic
lesions and cardiac events despite lowering of HDL cholesterol in
randomized controlled trials.33,34 Among individuals with type 2
diabetes, a plant-based diet improves glycemic control and
reduces body weight and plasma lipid concentrations.15
Strengths of the study include a geographically diverse
population, the use of a simple intervention that is highly
reproducible in other corporate locations and sufﬁcient statistical
power to demonstrate signiﬁcant changes. Limitations of the
study were underrepresentation of males for reasons that are not
clear and lack of the data on physical activity. The participants
were asked not to alter the exercise patterns during the study. We
are not sure whether they followed the recommendation.
Participants were self-selected and represent a small fraction of
the total workforce, in part because normal-weight, non-diabetic
individuals were excluded. However, it is not necessary to engage
an entire employee group in health promotion activities in order
to achieve substantial economic beneﬁts, because health risks and
medical expenditures tend to be concentrated in a small
population of employees.35 There was an attrition rate of 34% in
the intervention group. However, an intention-to-treat analysis (in
which dropouts were deemed to have had no change from
baseline) and an analysis for study completers yielded similar
results. Recruitment fell short of the sample size called for by the
power analysis. Nonetheless, signiﬁcant results were achieved for
key variables, suggesting that the power analysis may have
provided an overestimation of sample size. Although our study
establishes the important ﬁnding that a large corporate setting
can indeed implement a plant-based diet intervention in widely
diverse geographical locations and can achieve clinically
important results in a 4-month period, the long-term
sustainability is a separate issue. However, a similar intervention
was sustained over a 2-year period in a study by the current
investigators.26
In summary, a simple nutrition intervention at the place of
employment, tested in widely divergent regions of the United
States, yielded signiﬁcant improvements in indicators associated
with medical risk. Further studies should explore means of
implementing nutritional interventions widely, particularly for
individuals at greatest risk. This nutrition program can easily
be implemented in large corporate worksites to conduct
further studies exploring the effects of diet on other sources of
disability and revenue loss such as depression, anxiety and work
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productivity. These ﬁndings can be used to encourage worksites to
offer low-fat plant-based options in their cafeterias as well as offering
a weekly, ongoing nutrition education group, an online discussion
board and other forms of support for staff and employees.
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